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Background: Thrombospondins (THBSs) are a family of multidomain and secreted matricellular Ca2+-binding
glycoproteins which has at least five members encoded by independent genes. As a THBSs family member,
Thrombospondin2 (THBS2) has been reported to regulate angiogenesis. Nevertheless, the functions and clinical
significance of THBS2 still remains unclear in gastric cancer.
Methods: The mRNA and protein expression levels of THBS2 were assessed in 14 paired of gastric cancer specimens
and corresponding normal mucosas using quantitative real-time PCR and western blot analysis. Immunohistochemistry
of THBS2 and CD34 on population-based tissue microarrays consisting of 129 gastric cancer cases were used to
evaluate the prognostic significance of THBS2 and microvessel density (MVD) of each sample. Survival analyses
were performed by Kaplan–Meier method and Cox’s proportional hazards model. Colony formation assay,
endothelial cell tube formation assay, cell migration assay and apoptosis analysis in MKN-45 and SGC-7901 cell
lines were carried out to evaluate the effects of THBS2 on gastric cancer in vitro.
Results: 85.71% (12 of 14) gastric cancer tissues expressed remarkably lower THBS2 in both mRNA and protein
levels than the corresponding normal controls. Consistently, tissue microarray (TMA) results showed THBS2
levels were also inhibited in gastric cancer tissues compared with the normal controls. Moreover, we observed
that patients with higher levels of THBS2 were significantly correlated with more favourable prognosis while
decreased THBS2 expression were associated with poorer histological grades of gastric cancer. Additionally, our
in vitro experiments further demonstrated that overexpression of THBS2 could impede both the proliferation rate and
the tube formation of Human umbilical vein endothelial cells (HUVECs) in MKN-45 and SGC-7901 cell lines.
Conclusion: Our study suggests THBS2 is aberrantly expressed in gastric cancer and plays a critical role in cancer
progression, which can be a potential prognosis predictor of gastric cancer.
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Gastric cancer is a highly aggressive and lethal malignancy.
A total of 952,000 new stomach cancer cases and 723,000
deaths were estimated to have occurred in 2012, accounting
for 6.8% of the total cases and 8.8% of total deaths.
Moreover, Both new cases and deaths of gastric cancer
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unless otherwise stated.of that in the world [1]. Therefore great concerns are
raised for the researches of gastric cancer.
Thrombospondins (THBSs) are a family of multidomain
and matricellular Ca2+-binding glycoproteins secreted by
stromal fibroblasts, endothelial cells and immune cells [2].
They have at least five members encoded by independent
genes. By binding with numerous target proteins, they
participate in diverse biologic processes such as angiogen-
esis, cell motility, apoptosis, cytoskeletal organization, and
serve as interaction platforms in the extracellular matrix
(ECM) [3,4]. Notably, THBS1 and THBS2 are special in
this family for their type I repeats and both of them are
mainly shown as inhibitors of angiogenesis [5,6], one key
part of cancer research [7-9]. Microvessel density (MVD). This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genesis in tumours with CD34 being the microvessel
maker in gastric cancer [10]. Based on the previous find-
ings [2], we put forward a hypothesis in our study that it
could also affect the angiogenesis in gastric cancer.
Besides angiogenesis, THBS2 has been reported to
interact with multiple cell receptors, growth factors and
ECM proteins as well as regulate apoptosis, cell prolifer-
ation and adhesion [11]. In cancer researches, increasing
attentions have been focused on THBS2. Tokunaga et al.
[12] found that THBS2 expressed in patients with colon
cancer exhibited a significant lower risk of hepatic metas-
tases and tumour vascularity compared with the patients
whose tumours were THBS2 deficiency. Furthermore, De
Fraipont et al. [13] demonstrated that THBS2 was signifi-
cantly correlated with clinical status and outcome, and for
most tumours, there was an inverse correlation between
the THBS2 expression level and the degree of their ma-
lignancy. In addition, THBS2 also played a key role in
breast cancer [14], myeloma [15], malignant melanoma
[16], prostate cancer [17] and pulmonary adenocarcinoma
[18,19]. In gastric cancer, other members of THBSs,
THBS1 [20] and THBS4 [21] could be as a prognostic
biomarker or a powerful marker for diffuse-type gastric
adenocarcinomas. However, the detailed function of
THBS2 in gastric cancer and its implications for clinical
diagnose still remain dismal. Thus, we attempted to
unveil the clinical significance of THBS2 and its effect
in gastric cancer.
To verify our aforementioned hypothesis, we examined
the THBS2 expression levels in human gastric cancer
tissues and corresponding normal tissues and then ex-
plored the possible correlations between the expression
of THBS2 and clinicopathological features, clinical prog-
nosis and the MVD counting in patients with gastric can-
cer. In addition, colony formation assay, endothelial cell
tube formation assay, cell migration assay and apoptosis
analysis were carried out in MKN-45 and SGC-7901 cell
lines to explore the in vitro effect of THBS2 in gastric
cancer cells.
Results
Patient characteristics and clinical outcomes
In the present study, we enrolled 129 eligible patients,
which consisted of 101 males and 28 females. The age of
the patients ranged from 29 to 80 years (y) with a median
age of 61y. All the clinicopathological characteristics are
summarized in Table 1. The median overall survival (OS)
of the patients was 57 months, and mean OS was 44.01
[95% confidence interval (CI) 39.78-49.24 months].
THBS2 is down-regulated in gastric cancer
In order to determine the expression levels of THBS2 in
gastric cancer, we first evaluated the mRNA expressionlevels of THBS2 in gastric cancer by quantitative real-time
in the second cohort. This cohort of samples, mentioned
in Methods, included 14 human gastric cancer and the
corresponding normal tissues. As shown in Figure 1A,
THBS2 levels were markedly lower in 85.7% (12 of 14) of
the gastric cancer tissues than its normal controls, while
the remaining two pairs of the samples exhibited the op-
posite. Then, we detected the protein expression levels of
THBS2 via western blot in the same cohort. As show in
Figure1B and C, we observed that THBS2 protein expres-
sion levels were decreased in 85.7% (12 of 14) of the
tumour samples compared with its corresponding con-
trol, while sample 5 and 11 displayed inversely. To con-
firm this finding, we further performed a tissue
microarray (TMA) and assessed the protein expression
levels of THBS2 according to the immunoreactivity score
(IRS) of each sample. We found THBS2 proteins were
mainly expressed in the cytoplasms of gastric cells (Fig-
ure 2A), and in accordance with the results of western
blot, the levels of THBS2 were significantly inhibited in
gastric cancer tissues compared with the normal controls
(Figure 2B, P < 0.05). Taken together, our results demon-
strates that THBS2 is down-regulated in gastric cancer in
both mRNA and protein levels.
THBS2 expression levels are inverse correlated with
histological grades of gastric cancer
To further clarify the clinical importance of THBS2, we
analysed the relationship between THBS2 protein expres-
sion and clinical features including age, gender, histo-
logical grade, tumour location, depth of invasion, lymph
node metastasis and TNM stage of gastric cancer patients
in THBS2-positive and negative groups. As shown in
Table 1, we found a significant inverse correlation with
the histological grades of gastric cancer (P < 0.01). The
histological grades of patients in THBS2-positive group
were more likely to be well and moderate, whereas
patients in THBS2-negative group tended to be poor and
other. However, we failed to discover any significance
statistically between the expression levels of THBS2 and
other clinical parameters. Collectively, our findings sug-
gest that THBS2 is inverse correlated with histological
grade of gastric cancer.
THBS2 expression levels are inverse correlated with MVD
in gastric cancer
Previous reports implied THBS2 could regulate tumour
angiogenesis [6], yet none was reported in gastric cancer.
Hence, we asked whether there were any correlations
between MVD and THBS2 expression levels as well as
other clinical parameters in our clinical samples. The
MVD in 129 gastric cancer specimens ranged from 0 to
120, with the median of 40 and mean of 48.12 ± 28.99
(mean ± SD) according to the immunoreactivity of CD34
Table 1 Association among clinicopathological variables and THBS2 expression and overall survival of gastric cancer
patients
Variables Negative Positive Total No. P valuea Overall survival OS
Log-Rank P b HR(95% CI)
No.(%) No.(%)
Age (y) 0.112 0.743
<61 24(38.1) 39(61.9) 63 1(reference)
≥61 35(53.0) 31(47.0) 66 1.09(0.67-1.77)
Gender 0.831 0.405
Male 47(46.5) 54(53.5) 101 1(reference)
Female 12(42.9) 16(57.1) 28 0.76(0.40-1.45)
Histological grade 0.005 0.011
Well and moderate 24(33.8) 47(66.2) 71 1(reference)
Poor and other 35(60.3) 23(39.7) 58 1.89(1.16-3.09)
Tumor location 0.419 0.204
Upper 27(40.3) 40(59.7) 67 1(reference)
Middle 15(53.6) 13(46.4) 28 1.66(0.86-3.18)
Lower 17(50.0) 17(50.0) 34 1.90(0.90-4.01)
Depth of invasion 0.271 0.001
T1-T2 9(34.6) 17(65.4) 26 1(reference)
T3-T4 50(48.5) 53(51.5) 103 11.60(2.83-47.45)
Lymph node metastasis 0.454 <0.001
Absent 17(40.5) 25(59.5) 42 1(reference)
Present 42(48.3) 45(51.7) 87 5.16(2.46-10.84)
TNM stage 0.283 <0.001
I-II 21(39.6) 32(60.4) 53 1(reference)
III-IV 38(50.0) 38(50.0) 76 7.14(3.52-14.49)
Bold value is statistically significant at P < 0.05, HR hazard ratio.
a, P value of clinicopathological variables and THBS2 expression.
b, P value of association between clinicopathological variables and overall survival of gastric cancer patients.
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cantly correlated with MVD. The MVD in THBS2-negative
group was much higher than that in THBS2-positive group
(P < 0.001). However, we could not observe any statistic
differences between MVD and other clinicopathologic fea-
tures including clinical prognosis in our samples (data not
shown). In conclusion, our discoveries demonstrate that
THBS2 is inverse correlated with MVD in gastric cancer.
THBS2 is significantly associated with clinical prognosis of
gastric cancer patients
To examine the relationship between THBS2 expression
and the clinical prognosis of gastric cancer patients, we
conducted survival analyses by univariate and multivariate
Cox’s proportional hazards regression model. As shown in
Table 1, we found histological grade, depth of invasion,
lymph node metastasis and TNM stage were statistically
significant factors for OS in univariate analysis. However,
since TNM stage also contains the information of depthof invasion and lymph node metastasis, we further per-
formed multivariate survival analyses with adjustment for
the histological grade and TNM stage. We noticed that
TNM stage (P <0.001) and THBS2 expression (P <0.01)
were both independent prognostic factors for the assess-
ment of patient outcomes. Higher TNM stage was a risk
factor for longer OS [P <0.001, HR (hazard ratio) = 7.23,
95% CI 3.55-14.69) and elevated expression of THBS2 was
yet a favourable factor for longer OS (P < 0.01, HR = 0.51,
95% CI 0.31-0.85). Moreover, Kaplan–Meier survival
analysis further confirmed that THBS2 expression was
significantly correlated with clinical outcomes (Figure 3,
P <0.01, n = 129). Patients with lower THBS2 expression
displayed a significantly shorter OS [median 36 months,
mean 40.07 ± 3.65 (mean ± SE) months], whereas patients
with higher THBS2 expression showed a favourable prog-
nosis [median 59 months, mean 53.70 ± 2.95 (mean ± SE)
months]. Together, our results demonstrate THBS2 is sig-
nificantly associated with the clinical prognosis of gastric
Figure 1 mRNA and protein expression level of THBS2 in 14 gastric cancer tissues and the corresponding normal tissue. (A) Relative
mRNA expression of THBS2 was detected by quantitative real-time PCR. Expression of normal tissues were normalized to 1.0 as indicated. (B) The
densitometry analysis results of the THBS2 bands were normalized to GAPDH using Image J. Expression of normal tissues were normalized to 1.0
as indicated. (C) Relative protein expression of THBS2 was estimated by Western blot assay.
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for gastric cancer.
Overexpression of THBS2 inhibits the growth of gastric
cancer cells in vitro
Because THBS2 was significantly down-regulated in
gastric cancer, we inferred that THBS2 might inhibit
growth, promote apoptosis and enhance the migration
ability of gastric cancer cells. To verify our hypothesis,
we first constructed one lentiviral vector to stable
express THBS2 transcripts in gastric cancer cell lines.
Altered expression of THBS2 in 293 T cells was con-
firmed by western blot analysis (Figure 4A). Then, we
chose MKN-45 and SGC-7901 cell lines for our
in vitro study because the mRNA expression levels of
THBS2 were lower than others (data not shown). We
then performed the colony formation assay to evaluate
the effects of THBS2 on the growth of MKN-45 and
SGC-7901 cells. As shown in Figure 4B, we found cells
with THBS2 overexpression formed significantly fewer
colonies on soft agar compared with those of control
vector–infected cells (P < 0.01 for MKN-45 cells and
P < 0.001 for SGC-7901 cells, respectively). Moreover,
we examined the apoptosis levels between the two
groups in both cell lines and discovered that THBS2
promoted apoptosis in SGC-7901 cells (Figure 4F)but not in MKN-45 cells (Additional file 1: Figure S1A).
And there were no significant differences between the two
groups in SGC-7901 and MKN-45 cell lines in cell migra-
tion according to the transwell assays (Additional file 1:
Figure S1B and C). In summary, our data support that
THBS2 impedes the growth of gastric cancer cells in vitro
possibly via the regulation of apoptosis.
THBS2 suppresses gastric cancer angiogenesis in vitro
THBS2 is known as an inhibitor of angiogenesis [2]. To
provide evidences of THBS2 regulates the angiogenic
phenotype of gastric cancer, endothelial cell tube formation
assays were carried out. As shown in Figure 4E and D, in
both MKN-45 and SGC-7901 cell lines, human umbilical
vein endothelial cells (HUVECs) cultured with the medium
from THBS2-overexpression gastric cancer cells showed
significantly lower AngiogenicIndexCh1 than the negative
control (P < 0.05 for MKN-45 cells and P < 0.001 for SGC-
7901 cells, respectively ). Collectively, our results imply that
THBS2 suppresses the angiogenesis of gastric cancer cells
in vitro.
Discussion
THBS2 is known as a natural potent inhibitor of angio-
genesis and a modulator of the remodelling process
[22,23]. However, none of the former researches discussed
Figure 3 Kaplan–Meier survival analyses with Log-Rank test
for overall survival (OS). Kaplan-Meier analysis of the correlations
between different THBS2 expression levels and OS in 129 gastric
cancer patients.
Figure 2 Immunohistochemical analysis of THBS2, CD34. (A) Representative images of THBS2 and CD34 expression: N1, N2, N3,
N4, normal gastric tissue (N); M1, M2, M3, M4, moderately differentiated (M); P1, P2, P3, P4, poorly differentiated (P). Magnification:
100× (N1, M1, P1, N3, M3, P3), 200× (N4, M4, P4) and 400× (N2, M2, P2). (B) Comparison of THBS2 expression of gastric cancer
(n = 129) and normal gastric tissues (n = 24) in TMA. The THBS2 expression level presented as mean ± SEM. (C) Comparison of MVD
in THBS2-positive gastric cancer group (n = 70) and THBS2-negative gastric cancer group (n = 59). Dots represent MVD of each
samples. Values are means ± SEM.
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cancer.
Firstly, we found that mRNA and protein expression
levels of THBS2 were down-regulated in most samples.
However, one previous research reported THBS2 mRNA
expression levels in gastric cancer were higher than nor-
mal control [24]. Considering the limited sample size in
this study, which incorporated only 6 tissue specimens, it
is possible for this difference due to tumour heterogeneity
for two pairs of our second cohort did also show the same
patterns. Yet our subsequent result of TMA, larger in
sample size, was consistent with the result from the
second cohort. Taken together, we believed that THBS2
was more likely to be down regulated in gastric cancer cell
versus normal mucosa.
Moreover, we also noticed that the relative expression
of the samples exhibited differently in mRNA and protein
level. Lacking sufficient evidences, we infer that the func-
tion of THBS2 within gastric cancer cells may be regulated
by some intracellular upstream signalling factors, protein
ubiquitination, and other possible manners, which may
affect the protein levels of THBS2 and the phenotypes in
gastric cancer cells. And further emphasis can be put on
Figure 4 Overexpression of THBS2 inhibited the proliferation of gastric cancer cells, suppressed the angiogenesis of gastric cancer,
and promoted apoptosis in SGC-7901 cell line in vitro. (A) Western blot analysis of Flag in 293 T cells with THBS2 overexpression. (B) Colony
number analysis for MKN-45 and SGC-7901 cells with THBS2 overexpression and negative control. Values are means ± SD from three independent
experiments. (C) Images of colony formation assay. (D) AngiogenicIndexCh1 analysis of endothelial cell tube formation assay. Values are means ± SD.
(E) Images of endothelial cell tube formation assay. (F) Analysis of apoptosis in MKN-45 cell line. Values are means ± SD.
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of the samples from our second cohort displayed the same
expression patterns between mRNA and protein levels.
Secondly, our data showed that THBS2 could promote
apoptosis only in SGC-7901 cells but not in MKN-45
cells. Former researches showed that an N-terminal recom-
binant fragment of THBS2 could activate CD36-mediated
endothelial cell apoptosis [14], and the combination of
CD36 and THBS2 could activate the caspase signalling
pathway [25]. Thus, we assumed that the heterogeneity of
the two cell lines used in our study, like differentiated
CD36 expressions, might partly be the reason of different
levels of apoptosis induced by THBS2, which called for
further investigations.
Thirdly, our results showed that THBS2 could suppress
angiogenesis of gastric cancer. It is known that tumour
proliferation, invasion, or metastasis are dependent on
angiogenesis [26]. And based evidences support our dis-
covery and point out that the possible mechanisms that
THBS2 inhibits angiogenesis: 1) an apoptosis-independentfashion by inducing endothelial cell apoptosis, cell cycle
arresting and decreasing of endothelial cell migration
[27], 2) dependent on caspase signalling pathway acti-
vated by CD36 [28]. 3) functioning as co-receptors for
the low density lipoprotein receptor related protein
(LRP1), which could clear the complexes of THBS2 with
matrix metalloproteinases-2, -9 or vascular endothelial
growth factor (VEGF) from the pericellular environment
of mesenchymal cells [29-32].
Lastly, MVD is one of the most commonly used param-
eters to assess the degree of tumour angiogenesis and pre-
vious studies have found MVD could be an independent
prognostic factor in gastric cancer and other tumour
[33-35]. In our study, we found MVD was significantly
correlated with THBS2 protein expression (P < 0.001) in
gastric cancer, but not with clinical features and clinical
prognosis. These results demonstrated that THBS2 could
affect angiogenesis in gastric cancer, nevertheless, because
of no correlation between MVD and prognosis in our
samples, we suspected that higher THBS2 expression
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ing angiogenesis of gastric cancer, other mechanisms such
as regulating ECM remoulding [23] and proliferation rate
of gastric cancer cells might also be the reasons that need
further researches to explore.
Collectively, our findings emphasized on the important
roles of THBS2 in prognostic significances as well as
tumour proliferation and angiogenesis in gastric cancer.
These data suggest THBS2 could be an important prog-
nostic marker for gastric cancer patients. Moreover, based
on the effects of THBS2 on tumour development and
angiogenesis, our researches provide valuable clues for
clinical practices to develop molecular inhibiting thera-
peutics using targets deduced from the biological know-
ledge provided by the THBS2 signature.
Conclusion
Our study presents the first line of evidences that THBS2
expression is down-regulated at both mRNA and protein
levels and decreased THBS2 expression is associated with
the poor histological grade of gastric cancer. Crucially,
overexpression of THBS2 has a significant correlation
with favourable prognosis of gastric cancer patients. On
the other hand, THBS2 affected prognosis in gastric
cancer may not only through regulating the angiogen-
esis, but in some other manners like regulating ECM
remoulding and inhibiting the proliferation of gastric
cancer cells. These findings suggest that THBS2 could
be a potentially critical role of in the pathogenesis and
progression of gastric cancer. We confirm that, with the
gradual depth studies of THBS2, it may be a promising
useful and simple biomarker for predicting clinical out-
come for gastric cancer patients.
Methods
Patients and tissue specimens
In the present study, we incorporated two cohorts of
specimens. The first cohort contained 129 formalin-fixed,
paraffin-embedded human gastric cancer and 24 ran-
domly selected normal gastric tissues. They were consecu-
tively recruited between December 2006 and May 2008
from Department of General Surgery, The First Affiliated
Hospital of Anhui Medical University, Hefei, China. These
specimens were incorporated into TMA for immunohis-
tochemical staining. Histological features of these speci-
mens were confirmed by pathologists. Pathological TNM
staging was evaluated according to the 2010 criteria of
The American Joint Committee on Cancer (AJCC). The
second cohort was composed of 14 gastric cancer patients
who undergone tumour resection therapy at the Eighth
Department of General Surgery, The First Affiliated
Hospital of Anhui Medical University. The fresh gas-
tric cancer tissue and corresponding normal mucosa
(at least 5 cm distant from the tumour edge) wereimmediately frozen in liquid nitrogen and stored
at -80°C until using for Quantitative real-time PCR
and Western blot analysis. Patients in both cohorts did
not receive preoperative chemotherapy and/or radi-
ation. Written informed consent was provided by all
participants. All specimens were handled anonymously
according to the ethical standards. This study was
conducted with the approval of the Ethical Review Com-
mittee of the hospital.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from the second cohort using
Trizol reagent (Invitrogen) according to the manufac-
turer’s protocol. cDNA was synthesized by random
primers and Superscript II reverse transcriptase (Toyobo,
Osaka, Japan). The primers used for amplification for
THBS2: forward primer 5’-CGTGGACAATGACCTTG
TTG-3’ and reverse primer 5’-GCCATCGTTGTCATC
ATCAG-3’. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was amplified in the same q-PCR as an internal
control using primers: forward primer 5’-AGCCACATC
GCTCAGACAC-3’ and reverse primer 5’-GCCCAATA
CGACCAAATCC-3’. The reaction ran on the ABI 7900HT
Sequence Detection System (Applied Biosystems, CA,
USA) in the presence of SYBR-Green dye (Toyobo,
Osaka, Japan). The reaction condition was a denaturation
program (95°C for 5 min), and an amplification and quan-
tification program for 40 cycles (95°C for 15 s and 60°C
for 45 s). Every sample was tested in triplicates, and a
melting curve analysis of each sample was used to check
the specificity of amplification. The expression level was
determined as a ratio between THBS2 and the internal
control GAPDH in the amounts of mRNA calculated by
comparative CT method.
Protein extraction and Western blot
Total protein were extracted from 14 frozen gastric
cancer and its corresponding normal mucosa tissue by
ice in radio immunoprecipitation assay Lysis Buffer
(RIPA; Beyotime institute of Biotechnology, Jiangsu,
China), and measured using a BCA protein assay kit
(Beyotime institute of Biotechnology, Jiangsu, China).
The lysate was centrifuged at 12000 rpm for 5 minutes,
and the supernatant was heated at 100°C for 5 minutes.
Then equivalent proteins of each pair specimens were
separated on 8% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and electrotransferred to polyvinylidene
fluoride membranes (Millipore, Billerica, MA). After
The blocked with TBST containing 5% skim milk in at
room temperature for one hour ,the membranes were
blotted with anti-THBS2 antibody (1:1500; Novus) and
anti-Flag (1:3000; Sigma). Followed membranes incuba-
tion with horseradish peroxidase–labelled anti-rabbit and
anti-mouse IgG as the secondary antibody (Beyotime
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Aogma) was used as a loading control antibody. The bound
antibodies were detected with the enhanced chemilumines-
cence method.Immunohistochemistry and TMA analysis
Gastric cancer and normal gastric mucosa specimens
were formalin-fixed, paraffin-embedded and were used
to construct a tissue TMA. H&E-stained slides were
screened to identify optimal intratumoural tissue for
analysis. 4-μm thick sections were baked at 60°C for
1 hour, deparaffinised with xylenes, and rehydrated in
graded ethanol to distilled water. Antigen retrieval was
achieved with placing the sections with citrate buffer in
a rice steamer for 30 minutes. To quench the endogen-
ous peroxidase activity, the sections were treated with
3% H2O2 in methanol. Then we used 1% bovine serum
albumin to block the nonspecific binding. Anti-THBS2
antibody (Novus, 1:2000) and anti-CD34 (Abcam, 1:250)
were incubated with the sections at 37°C overnight, then
incubated with horseradish peroxidase-labelled Anti-rabbit
IgG as the secondary antibody (Life Technologies). In the
end, slides were placed on an autostainer link instrument
and proceed with staining. For negative controls, the
primary antibodies were replaced with normal rabbit
serum. The final effective immunohistochemical stain-
ing was evaluated by two independent pathologists
without knowing the information of patients according
to the staining intensity and extent of staining. Tissue
section was scored as the percentage of stained cyto-
plasm in gastric cancer gland cells and normal gland
cells (0 points for no cells stained, 1 point for <25%, 2
points for 25-75%, and 3 points for >75% of cells stained),
and the staining intensity of immunoreactivity was graded
on a scale of 0 to 3. The immunoreactivity score (IRS)
was resulted from the multiplication of both parameters.
Specimens were scored as follows: negative (IRS = 0 ~ 2),
positive (IRS = 3 ~ 9).MVD counting
Immunohistochemical staining of CD34 and generally
accepted criteria performed by Weidner et al. [36] were
used for MVD counting. Any stained endothelial cells or
endothelial cell clusters were separated from adjacent
microvessels, and the thickness of every vessel wall over
2.75 μm would be excluded. Three separate sections
containing hot-spots (where the highest number of
discrete microvessels was stained) in each sample of
TMA were chosen in low magnifications (100×) under a
light microscope (Leica, Germany). Subsequently, micro-
vessels were counted in each section in high magnification
(200×). Final counts were expressed as the average of all
the three sections examined.Cell culture and lentivirus infection
Gastric adenocarcinoma cell line MKN-45 and SGC-7901
were obtained from the Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences. These two cell
lines were grown in RPMI1640 medium (Gibco, USA)
supplemented with 10% fetal bovine serum (FBS, Gibco,
USA), and incubated at 37°C in a humidified atmosphere
with 5% CO2. The maintenance of MKN-45 and SGC-
7901 cell lines were described previously [37]. Human
293 T cells were maintained in DMEM with 10% fetal
bovine serum (Gibco, USA). To generate cell lines overex-
pressing THBS2, the open reading frame of THBS2
[GenBank:NM_003247.3] was cloned into the lentiviral
vector GV287 (Ubi-MCS-3FLAG-SV40-EGFP; GeneChem
Co., Ltd), and GV287 empty vector served as negative
control (NC) for Ubi-THBS2-3FLAG-SV40-EGFP. The
procedures of packaging and infection of lentivirus were
according to the previous study [38].
Colony formation assay
Colony formation was performed as described previously
[39,40]. 8 × 102 cells suspended in DMEM medium con-
taining 10% fetal bovine serum were plated in 6-well
plates. The plates were incubated at 37°C in a 5% CO2 in-
cubator for 14 days or colonies with more than 50 cells
were counted. Each dose was done in triplicate, and the
experiments were done at least three times.
Endothelial cell tube formation assay
The tube formation assay was done as described previ-
ously [41]. 70 μL of Matrigel Basement Membrane Matrix
(BD Biosciences) were pipetted into each well of a 96-well
plate and polymerized for 30 minutes at 37°C. HUVECs
were harvested after trypsin treatment and suspended in
conditioned medium from THBS2 overexpression group
and NC group. Then 2 × 104 HUVECs with these condi-
tioned medium were added to each well and incubated at
37°C, 5% CO2, for 20 hours. The cultures were stained
with Cellomics Cytoskeletal Rearrangement Kits (Thermo
Fisher Scientific) according to the protocol by the com-
pany and analysed with Cellomics (Thermo Fisher Scien-
tific). The measurement is AngiogenicIndexCh1 which is
defined as 1000 × Total Area of Connected Tubes/Total
Image Area(Thermo Fisher Scientific provided).
Cell migration assay
Cell migration assays were examined according to previous
study [42]. 1 × 105 cells in 100 μL DMEM medium without
FBS were seeded on a fibronectin coated polycarbonate
membrane insert in a Transwell apparatus (Corning, NY,
USA). 600 μl DMEM containing 10% FBS was added into
the lower chamber. When the 20 hours incubation was
completed, cells were fixed with methanol and stained
with Giemsa. Cell numbers on the lower side of the filter
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http://www.molecular-cancer.com/content/13/1/225were counted under a light microscopy (Olympus micro-
publisher 3.3RTV). Each dose was done in triplicate, and
the experiments were done at least three times.
Apoptosis analysis
Apoptosis analysis was described in detail previously [37].
These assays used apoptosis kit (eBioscince, USA ) follow-
ing to the manufacturer’s instructions. The stained cells
were analysed by flow cytometry (FACSCalibur, BD).
Statistical analysis
SPSS 15.0 software (SPSS, Inc. Chicago) was used for all
statistical analyses. Fisher’s exact test or The Pearson χ2
test was used to analyse the relationship between THBS2
protein expression level and the clinicopathologic features.
Mann-Whitney U test used for comparing MVD with
THBS2 expression and clinicopathologic features as well
as the protein expression level between gastric cancer
tissue and normal tissue in the TMA. Survival curves
calculation and OS curve plotting used the Kaplan–
Meier method, and the Log-Rank test was applied to
compare the distribution between groups. Multivariate
Cox’s proportional hazards models were used to explore
the effects of the clinicopathologic variables with THBS2
protein expression level on survival. Comparisons of quan-
titative data were analyzed by Student’s t-test between two
groups (two-tailed). *, **, or *** indicates P < 0.05, P < 0.01,
or P <0.001, respectively. P < 0.05 was defined as statistically
significant.
Additional file
Additional file 1: Figure S1. Apoptosis analysis of MKN-45 cell line and
cell migration assay. (A) Analysis of apoptosis in MKN-45 cell line. Values
are means ± SD. (B) Migration number counted and analysis under
400× microscope. (C) Images of colony migration assay (400×).
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